AMPH has been the topic of several other research reports. Wells Fargo & Co set a $29.00 price objective on Amphastar Pharmaceuticals and gave the stock a buy rating in a report on Thursday, June 6th. TheStreet upgraded Amphastar Pharmaceuticals from a c rating to a b- rating in a report on Wednesday, August 7th. Finally, Zacks Investment Research upgraded Amphastar Pharmaceuticals from a hold rating to a buy rating and set a $23.00 price objective on the stock in a report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $24.64.
AMPH opened at $22.24 on Thursday. The company has a market cap of $1.07 billion, a P/E ratio of 105.90 and a beta of 1.35. The business’s 50-day moving average price is $20.40 and its 200-day moving average price is $21.31. The company has a current ratio of 2.81, a quick ratio of 1.83 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a 12 month low of $17.71 and a 12 month high of $25.43.
In related news, CFO William J. Peters sold 4,942 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $21.00, for a total transaction of $103,782.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jason B. Shandell sold 6,615 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $20.31, for a total value of $134,350.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,557 shares of company stock worth $549,583. 30.80% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Amphastar Pharmaceuticals by 1.5% during the 2nd quarter. BlackRock Inc. now owns 5,927,141 shares of the company’s stock valued at $125,124,000 after purchasing an additional 87,107 shares during the period. Vanguard Group Inc. increased its holdings in Amphastar Pharmaceuticals by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 2,381,761 shares of the company’s stock valued at $50,279,000 after purchasing an additional 57,349 shares during the period. Federated Investors Inc. PA increased its holdings in Amphastar Pharmaceuticals by 8.7% during the 1st quarter. Federated Investors Inc. PA now owns 1,472,931 shares of the company’s stock valued at $30,092,000 after purchasing an additional 117,480 shares during the period. Renaissance Technologies LLC increased its holdings in Amphastar Pharmaceuticals by 33.2% during the 2nd quarter. Renaissance Technologies LLC now owns 588,000 shares of the company’s stock valued at $12,413,000 after purchasing an additional 146,400 shares during the period. Finally, Nuveen Asset Management LLC purchased a new position in Amphastar Pharmaceuticals during the 2nd quarter valued at about $12,134,000. Institutional investors own 48.12% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Featured Story: Stochastic Momentum Index (SMI)
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.